Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 3 1Phase 2/3 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3Triple Negative Breast Neoplasms 1Neoplasms, Plasma Cell 1Breast Neoplasms 1

Interventions

Dexamethasone 132Lenalidomide 58Bortezomib 56Calcium Dobesilate 44Melphalan 41carfilzomib 38pomalidomide 36Cyclophosphamide 35daratumumab 23belantamab mafodotin 21Peripheral Blood Stem Cell Transplantation 17ixazomib 16dexamethasone acetate 13Filgrastim 13Bendamustine Hydrochloride 13fludarabine phosphate 12fludarabine 12dexamethasone 21-phosphate 12Tacrolimus 12auricularum 11Whole-Body Irradiation 11liposomal doxorubicin 10iberdomide 10Prednisone 10venetoclax 9selinexor 9isatuximab 9Mycophenolic Acid 9pembrolizumab 8Cyclosporine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Multiple Myeloma × Aspirin × Clear all
NCT00790842 2018-10-24

PrE1003

PrECOG, LLC.

Phase 1/2 Terminated
63 enrolled 14 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01355705 2018-09-18

Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

Stanford University

Phase 1/2 Completed
14 enrolled 9 charts
Plasma cell

Multiple Myeloma

NCT00833833 2016-04-27

MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

Celgene Corporation

Phase 1/2 Completed
259 enrolled 31 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡